2017
Ability to Reach Low-Income Smokers Enrolled in a Randomised Controlled Trial Varies with Time of Month
Hawk K, Shi R, Weiss J, Makuch R, Toll B, Bernstein SL. Ability to Reach Low-Income Smokers Enrolled in a Randomised Controlled Trial Varies with Time of Month. The Journal Of Smoking Cessation 2017, 13: 227-232. PMID: 31452822, PMCID: PMC6709708, DOI: 10.1017/jsc.2017.23.Peer-Reviewed Original ResearchLow-income smokersWeek 4Week 1Time of monthTobacco dependence treatmentOne-month followControlled TrialsAcademic EDEmergency departmentDependence treatmentWeek 2SmokersLow-income populationsWeek 3Study participantsMonthsFollowPhone callsLow-income individualsSuccessful contactTrialsFuture studiesParticipantsCellphone serviceUrban communities
2010
Nicotine dependence as a moderator of a quitline-based message framing intervention
Fucito LM, Latimer AE, Carlin-Menter S, Salovey P, Cummings KM, Makuch RW, Toll BA. Nicotine dependence as a moderator of a quitline-based message framing intervention. Drug And Alcohol Dependence 2010, 114: 229-232. PMID: 21036492, PMCID: PMC3044773, DOI: 10.1016/j.drugalcdep.2010.09.012.Peer-Reviewed Original ResearchConceptsMessage framing interventionsNicotine dependence scoresGain-framed messagesNicotine dependenceDependence scoresMore cigarettesPoint prevalence smoking abstinenceNew York State Smokers' QuitlineSmoking cessation treatmentHigh nicotine dependenceState Smokers' QuitlineBaseline total scoreHigher nicotine dependence scoresNicotine dependence levelHigher dependence scoresNicotine medicationsNicotine patchCessation treatmentDependent smokersSmoking abstinenceSmokersSmoking outcomesTotal scoreFraming interventionQuitlineLow-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial
Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O’Malley S. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial. Drug And Alcohol Dependence 2010, 111: 200-206. PMID: 20542391, PMCID: PMC3771701, DOI: 10.1016/j.drugalcdep.2010.04.015.Peer-Reviewed Original ResearchConceptsWeight gainSmoking cessationPoint prevalence smoking abstinence ratePre-specified primary outcomesLow-dose naltrexoneOpen-label therapySmoking abstinence ratesPoint prevalence abstinenceReduced weight gainNaltrexone augmentationPlacebo groupNicotine replacementPrimary outcomeQuit dateAbstinence ratesLabel therapyNicotine patchBehavioral counselingNaltrexoneAbstinent participantsSmokersWeight concernsWeeksCessationLower rates
2009
GABAA‐benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression
Esterlis I, Cosgrove KP, Batis JC, Bois F, Kloczynski TA, Stiklus SM, Perry E, Tamagnan GD, Seibyl JP, Makuch R, Krishnan‐Sarin S, O'Malley S, Staley JK. GABAA‐benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression. Synapse 2009, 63: 1089-1099. PMID: 19642218, PMCID: PMC2778224, DOI: 10.1002/syn.20688.Peer-Reviewed Original ResearchConceptsSpielberger State-Trait Anxiety IndexState-Trait Anxiety IndexDepressive symptomsSubsyndromal anxietyAnxiety symptomsPain toleranceReceptor availabilityAbstinent tobacco smokersSex-matched nonsmokersSingle photon emissionPain symptomsHealthy ageSmoking statusTobacco smokersSubsyndromal depressionAbstinent smokersVulnerable smokersCold pressor taskNonsmokersGamma-aminobutyricEpidemiology ScaleSmokersAcute abstinenceBrain areasSymptoms